Procept Biorobotics
PRCT
Market cap $4.81B

88.94 USD

+3.03

3.53%

At close Nov 15, 4:00 PM EST

After hours

87.24

-1.70

1.91%

1 day

3.53%

5 days

-12.18%

1 month

23.36%

3 months

41.17%

6 months

28.54%

Year to date

114.62%

1 year

170.17%

5 years

112.06%

10 years

112.06%

About: PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.

Employees: 626

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,704 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

192% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 24

33% more capital invested

Capital invested by funds: $2.75B [Q2] → $3.65B (+$902M) [Q3]

23% more funds holding

Funds holding: 198 [Q2] → 244 (+46) [Q3]

15% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 71

0.54% more ownership

Funds ownership: 87.53% [Q2] → 88.07% (+0.54%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 8 [Q2] → 8 (+0) [Q3]

9% less call options, than puts

Call options by funds: $23.3M | Put options by funds: $25.7M

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$75

16%

downside

Avg. target

$94

6%

upside

High target

$105

18%

upside

6 analyst ratings

5 positive

83%

1 neutral

17%

0 negative

0%

Jefferies Michael Sarcone 100% 1-year accuracy 1 / 1 met price target	7%upside $95	Hold Initiated	14 Nov 2024
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target	18%upside $105	Buy Reiterated	30 Oct 2024
Piper Sandler Matt O'Brien 60% 1-year accuracy 30 / 50 met price target	16%downside $75	Overweight Reiterated	8 Oct 2024
TD Cowen Joshua Jennings 65% 1-year accuracy 11 / 17 met price target	11%upside $99	Buy Maintained	16 Sept 2024
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target	7%upside $95	Buy Maintained	3 Sept 2024

See Analyst Rankings

Financial journalist opinion

Based on 12 articles about PRCT published over the past 30 days

Zacks Investment Research

Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice

Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of an underwritten public offering of 1,923,076 shares of its common stock, at a public offering price of $91.00 per share, before underwriting discounts and commissions, for aggregate gross proceeds of approximately $175 million. In addition, a selling stockholder has granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of the Company's common stock at the public offering price, less underwriting discounts and commissions. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The offering is expected to close on or about October 31, 2024, subject to customary closing conditions.

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

Zacks Investment Research

All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy

PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy

Investors Business Daily

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook

Medical stock Procept BioRobotics has surged past a buy point after third-quarter results beat estimates.

Medical Gear Stock Surges Past Buy Point On Upbeat Sales Outlook

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the commencement of an underwritten public offering of $175,000,000 of shares of its common stock. A selling stockholder also expects to grant the underwriters a 30-day option to purchase up to an additional $26,250,000 of shares of the Company's common stock. PROCEPT BioRobotics will not receive any proceeds from any sale of shares by the selling stockholder. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential

PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.

Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Executive Officer Sham Shiblaq - Chief Commercial Officer Kevin Waters - Chief Financial Officer Conference Call Participants Craig Bijou - Bank of America Securities Brandon Vasquez - William Blair Richard Newitter - Truist Josh Jennings - TD Cowen Chris Pasquale - Nephron Research Ryan Zimmerman - BTIG Brett Gasaway - Leerink Partners Operator Good morning and welcome to PROCEPT BioRobotics Third Quarter 2024 Earnings Conference Call. At this time all participants' are in a listen-only mode.

PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript

Investors Business Daily

Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise

Procept Biorobotics shares surged Monday after the robotic surgery player beat September-quarter expectations and hiked its outlook.

Procept Biorobotics, A Top 5% Stock, Makes A Bullish Move On Quarterly Beat And Raise

Zacks Investment Research

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.

PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2024.

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

See News Rankings

Charts implemented using Lightweight Charts™